Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Papillomavirus Infections × VGX-3100 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 2 Papillomavirus Infections 1

Interventions

Papillomavirus Vaccines 5 human papillomavirus vaccine, L1 type 16, 18 2 Vaccines 2 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2 halofantrine 1 fludarabine 1 VGX-3100 1 Radiotherapy 1 Polymerase Chain Reaction 1 Interleukin-2 1 Cyclophosphamide 1 Cidofovir 1 Carboplatin 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Inovio Pharmaceuticals

Phase 1 Completed

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡